SPR4-peptide alters bone metabolism of normal and HYP mice

Bone

Volumn 72, Issue , 2015, Pages 23-33

  Zelenchuk, Lesya V ^a   Hedge, Anne Marie ^a   Rowe, Peter S N ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

DMP1; FGF23; MEPE; PHEX; Rickets; Sclerostin

Indexed keywords

ALKALINE PHOSPHATASE; ASARM PEPTIDE; BETA CATENIN; DENTIN MATRIX PROTEIN 1; KLOTHO PROTEIN; MESSENGER RNA; OSTEOPONTIN; PEPTIDE DERIVATIVE; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; SCLEROSTIN; SPR4 PEPTIDE; UNCLASSIFIED DRUG; CTNNB1 PROTEIN, MOUSE; DMP1 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; GLYCOPROTEIN; LIGAND; PEPTIDE; PHEX PROTEIN, MOUSE; PHOSPHATE; PROTEIN BINDING; SCLEROPROTEIN; SOST PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE MINERALIZATION; CONTROLLED STUDY; CORTICAL BONE; DRUG ACTIVITY; DRUG BINDING; FEMUR; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSMOTIC PUMP; TRABECULAR BONE; URINALYSIS; WILD TYPE; X LINKED HYPOPHOSPHATEMIC RICKETS; ANIMAL; BONE; C57BL MOUSE; CHEMISTRY; DIET; DISEASE MODEL; FAMILIAL HYPOPHOSPHATEMIC RICKETS; GENE EXPRESSION REGULATION; GENETICS; KIDNEY; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; PATHOPHYSIOLOGY; PROTEIN MOTIF; TRANSGENIC MOUSE; X CHROMOSOME LINKED DISORDER;

AMINO ACID MOTIFS; ANIMALS; BETA CATENIN; BONE AND BONES; DIET; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX PROTEINS; FAMILIAL HYPOPHOSPHATEMIC RICKETS; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; GENETIC DISEASES, X-LINKED; GLYCOPROTEINS; IMMUNOHISTOCHEMISTRY; KIDNEY; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDES; PHEX PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PHOSPHATES; PROTEIN BINDING; RNA, MESSENGER; X-RAY MICROTOMOGRAPHY;

EID: 84912101750     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.11.011     Document Type: Article

References (55)

1. Rowe P.S., de Zoysa P.A., Dong R., Wang H.R., White K.E., Econs M.J., et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 2000, 67(1):54-68.
2. Salmon B., Bardet C., Khaddam M., Naji J., Coyac B.R., Baroukh B., et al. MEPE-derived ASARM peptide inhibits odontogenic differentiation of dental pulp stem cells and impairs mineralization in tooth models of X-linked hypophosphatemia. PLoS One 2013, 8(2):e56749.
3. Staines K.A., Mackenzie N.C., Clarkin C.E., Zelenchuk L., Rowe P.S., MacRae V.E., et al. MEPE is a novel regulator of growth plate cartilage mineralization. Bone 2012, 51(3):418-430.
4. Boskey A.L., Chiang P., Fermanis A., Brown J., Taleb H., David V., et al. MEPE's diverse effects on mineralization. Calcif Tissue Int 2010, 86(1):42-46.
5. Rowe P.S., Kumagai Y., Gutierrez G., Garrett I.R., Blacher R., Rosen D., et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 2004, 34(2):303-319.
6. Bresler D., Bruder J., Mohnike K.L., Fraser D., Rowe P.S.N. Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol 2004, 183:R1-R9.
7. Opsahl Vital S., Gaucher C., Bardet C., Rowe P.S., George A., Linglart A., et al. Tooth dentin defects reflect genetic disorders affecting bone mineralization. Bone 2012, 50(4):989-997.
8. David V., Martin A.C., Hedge A.M., Drezner M.K., Rowe P.S. ASARM peptides: PHEX-dependent & independent regulation of serum phosphate. Am J Physiol Renal Physiol 2011, 300(3):F783-F791.
9. Atkins G.J., Rowe P.S., Lim H.P., Welldon K.J., Ormsby R., Wijenayaka A.R., et al. Sclerostin is a locally acting regulator of late-osteoblast/pre-osteocyte differentiation and regulates mineralization through a MEPE-ASARM dependent mechanism. J Bone Miner Res 2011, 26(7):1425-1436.
10. Boukpessi T., Gaucher C., Leger T., Salmon B., Le Faouder J., Willig C., et al. Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine- and aspartate-rich motif peptide in human hypophosphatemic dentin. Am J Pathol 2010, 177(2):803-812.
11. David V., Martin A., Hedge A.M., Rowe P.S. Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology 2009, 150(9):4012-4023.
12. Martin A., David V., Laurence J.S., Schwarz P.M., Lafer E.M., Hedge A.M., et al. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 2008, 149(4):1757-1772.
13. Rowe P.S., Matsumoto N., Jo O.D., Shih R.N., Oconnor J., Roudier M.P., et al. Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone 2006, 39(4):773-786.
14. Rowe P.S.N., Garrett I.R., Schwarz P.M., Carnes D.L., Lafer E.M., Mundy G.R., et al. Surface Plasmon Resonance (SPR) confirms MEPE binds to PHEX via the MEPE-ASARM-motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 2005, 36(1):33-46.
15. Gowen L.C., Petersen D.N., Mansolf A.L., Qi H., Stock J.L., Tkalcevic G.T., et al. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 2003, 278(3):1998-2007.
16. Zhang L., Choi H.J., Estrada K., Leo P.J., Li J., Pei Y.F., et al. Multi-stage genome-wide association meta-analyses identified two new loci for bone mineral density. Hum Mol Genet 2014, 23(7):1923-1933.
17. Hsu Y.H., Kiel D.P. Clinical review: genome-wide association studies of skeletal phenotypes: what we have learned and where we are headed. J Clin Endocrinol Metab 2012, 97(10):E1958-E1977.
18. Zmuda J.M., Yerges-Armstrong L.M., Moffett S.P., Klei L., Kammerer C.M., Roeder K., et al. Genetic analysis of vertebral trabecular bone density and cross-sectional area in older men. Osteoporos Int 2011, 22(4):1079-1090.
19. Jemtland R., Holden M., Reppe S., Olstad O.K., Reinholt F.P., Gautvik V.T., et al. Molecular disease map of bone characterizing the postmenopausal osteoporosis phenotype. J Bone Miner Res 2011, 26(8):1793-1801.
20. Styrkarsdottir U., Halldorsson B.V., Gudbjartsson D.F., Tang N.L., Koh J.M., Xiao S.M., et al. European bone mineral density loci are also associated with BMD in East-Asian populations. PLoS One 2010, 5(10):e13217.
21. Alam I., Padgett L.R., Ichikawa S., Alkhouli M., Koller D.L., Lai D., et al. Sibling family genes and bone mineral density: association and allele-specific expression in humans. Bone 2014, 64:166-172.
22. Reijnders C.M., van Essen H.W., van Rens B.T., van Beek J.H., Ylstra B., Blankenstein M.A., et al. Increased expression of matrix extracellular phosphoglycoprotein (MEPE) in cortical bone of the rat tibia after mechanical loading: identification by oligonucleotide microarray. PLoS One 2013, 8(11):e79672.
23. Estrada K., Styrkarsdottir U., Evangelou E., Hsu Y.H., Duncan E.L., Ntzani E.E., et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet 2012, 44(5):491-501.
24. Jain A., Fedarko N.S., Collins M.T., Gelman R., Ankrom M.A., Tayback M., et al. Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density. J Clin Endocrinol Metab 2004, 89(8):4158-4161.
25. HYP-consortium Francis F., Hennig S., Korn b, Reinhardt R., de Jong D., Poustka A., et al. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 1995, 11(2):130-136.
26. Rowe P.S. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr 2012, 22(1):61-86.
27. Capparelli A.W., Roh D., Dhiman J.K., Jo O.D., Yanagawa N. Altered proximal tubule glucose metabolism in X-linked hypophosphatemic mice. Endocrinology 1992, 130(1):328-334.
28. Rifas L., Gupta A., Hruska K.A., Avioli L.V. Altered osteoblast gluconeogenesis in X-linked hypophosphatemic mice is associated with a depressed intracellular pH. Calcif Tissue Int 1995, 57(1):60-63.
29. Xie W., Mechin M.C., Dubois S.G., Lajeunesse D., van de Werve G. Up-regulation of liver glucose-6-phosphatase in x-linked hypophosphatemic mice. Horm Metab Res 2002, 34(6):288-292.
30. Zelenchuk L.V., Hedge A.M., Rowe P.S. PHEX mimetic (SPR4-Peptide) corrects and improves HYP and wild type mice energy-metabolism. PLoS One 2014, 9(5):e97326.
31. Lorenz-Depiereux B., Bastepe M., Benet-Pages A., Amyere M., Wagenstaller J., Muller-Barth U., et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006, 38(11):1248-1250.
32. Feng J.Q., Ward L.M., Liu S., Lu Y., Xie Y., Yuan B., et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006, 38(11):1310-1315.
33. Addison W., Masica D., Gray J., McKee M.D. Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J Bone Miner Res 2009, 25(4):695-705.
34. Addison W., Nakano Y., Loisel T., Crine P., McKee M. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite - an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res 2008, 23(10):1638-1649.
35. Barros N.M., Hoac B., Neves R.L., Addison W.N., Assis D.M., Murshed M., et al. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia. J Bone Miner Res 2013, 28(3):688-699.
36. Bouxsein M.L., Boyd S.K., Christiansen B.A., Guldberg R.E., Jepsen K.J., Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010, 25(7):1468-1486.
37. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2(6):595-610.
38. Ott S.M. Histomorphometric measurements of bone turnover, mineralization, and volume. Clin J Am Soc Nephrol 2008, 3(Suppl. 3):S151-S156.
39. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29(9):e45.
40. Shirley D.G., Faria N.J., Unwin R.J., Dobbie H. Direct micropuncture evidence that matrix extracellular phosphoglycoprotein inhibits proximal tubular phosphate reabsorption. Nephrol Dial Transplant 2010, 25(10):3191-3195.
41. Marks J., Churchill L.J., Edward S.D., Unwin R. The phosphatonin matrix extracellular phosphoglycoprotein (MEPE) inhibits renal intestinal phosphate transport in vivo. J Am Soc Nephrol 2008, 19(12):2313-2320.
42. Dobbie H., Unwin R.J., Faria N.J., Shirley D.G. Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption. Nephrol Dial Transplant 2008, 23(2):730-733.
43. Farrow E.G., Summers L.J., Schiavi S.C., McCormick J.A., Ellison D.H., White K.E. Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation. J Endocrinol 2010, 207(1):67-75.
44. Kogawa M., Wijenayaka A.R., Ormsby R., Thomas G.P., Anderson P.H., Bonewald L.F., et al. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2. J Bone Miner Res 2013, 28(12):2436-2448.
45. Bodine P.V., Komm B.S. Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord 2006, 7(1-2):33-39.
46. Caverzasio J., Manen D. Essential role of Wnt3a-mediated activation of mitogen-activated protein kinase p38 for the stimulation of alkaline phosphatase activity and matrix mineralization in C3H10T1/2 mesenchymal cells. Endocrinology 2007, 148(11):5323-5330.
47. Holmen S.L., Zylstra C.R., Mukherjee A., Sigler R.E., Faugere M.C., Bouxsein M.L., et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 2005, 280(22):21162-21168.
48. Zhang J., Zhang X., Zhang L., Zhou F., van Dinther M., Ten Dijke P. LRP8 mediates Wnt/beta-catenin signaling and controls osteoblast differentiation. J Bone Miner Res 2012, 27(10):2065-2074.
49. Makovey J., Macara M., Chen J.S., Hayward C.S., March L., Seibel M.J., et al. Serum uric acid plays a protective role for bone loss in peri- and postmenopausal women: a longitudinal study. Bone 2013, 52(1):400-406.
50. Nabipour I., Sambrook P.N., Blyth F.M., Janu M.R., Waite L.M., Naganathan V., et al. Serum uric acid is associated with bone health in older men: a cross-sectional population-based study. J Bone Miner Res 2011, 26(5):955-964.
51. Sritara C., Ongphiphadhanakul B., Chailurkit L., Yamwong S., Ratanachaiwong W., Sritara P. Serum uric acid levels in relation to bone-related phenotypes in men and women. J Clin Densitom 2012, 16(3):336-340.
52. Rafaelsen S.H., Raeder H., Fagerheim A.K., Knappskog P., Carpenter T.O., Johansson S., et al. Exome sequencing reveals FAM20c mutations associated with fibroblast growth factor 23-related hypophosphatemia, dental anomalies, and ectopic calcification. J Bone Miner Res 2013, 28(6):1378-1385.
53. Wang X., Wang S., Li C., Gao T., Liu Y., Rangiani A., et al. Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice. PLoS Genet 2012, 8(5):e1002708.
54. Vogel P., Hansen G.M., Read R.W., Vance R.B., Thiel M., Liu J., et al. Amelogenesis imperfecta and other biomineralization defects in Fam20a and Fam20c null mice. Vet Pathol 2012, 49(6):998-1017.
55. Tagliabracci V.S., Engel J.L., Wen J., Wiley S.E., Worby C.A., Kinch L.N., et al. Secreted kinase phosphorylates extracellular proteins that regulate biomineralization. Science 2012, 336(6085):1150-1153.